Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. develops and commercializes nitric oxide-based medical device and biopharmaceutical programs. Its recurring news centers on LungFit PH, a tankless inhaled nitric oxide system that uses Plasma Pulse Technology to generate nitric oxide from room air, and on commercial access through hospital purchasing channels.
Company updates also cover nitric oxide programs for respiratory indications, including severe lung infections, and Beyond Cancer's ultra-high concentration nitric oxide, or UNO, platform for investigational solid-tumor immunotherapy. Additional recurring themes include clinical data presentations, scientific publications, intellectual property, leadership changes, investor conferences, and governance matters.
Beyond Cancer, has been chosen to present on the clinical development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting. The company will host an event in Chicago featuring key opinion leaders to discuss the ongoing clinical development of UNO. Additionally, presentations at the ASCO Annual Meeting will showcase new data from the Phase 1 trial evaluating UNO101 in various malignancies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.